Outline

OBP-2001 and its analogues are compounds that specifically inhibits replication of SARS-CoV-2 virus, that causes COVID-19.
We entered into a joint research agreement with Kagoshima University in 2006 and have conducted drug discovery research. As a result, we have identified a group of compounds that have an efficacy to specifically inhibit replication on SARS-CoV-2 virus. In addition, we confirmed that our compounds were equally effective to or even better than the approved therapeutic drug, remdesivir from Gilead.
Various types of vaccines against SARS-CoV-2 virus have been developed around the world, however SARS-CoV-2 virus can be easily mutated. Therefore, it may be difficult to control the global pandemic only with vaccines. Thus, we will develop OBP-2001 and its analogues with a goal of completely suppressing the replication of SARS-CoV-2 virus.

Target indication

SARS-Cov-2 virus infection

Current status

Preclinical study in progress

• For progress of development, refer to "Outline of Our Pipeline: Progress chart of pipeline.
• For details, refer to "Research and Development Activities" in the latest financial statements.